Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05814055

The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence

This study will evaluate the compliance with a daily kava regimen among active smokers who have an intention to quit smoking. This study will also investigate whether kava use can facilitate tobacco cessation, reduce stress, and improve sleep.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Florida

Gainesville, Florida, 32608, United States

Location status: Recruiting

Location contact

Melissa Malham

CONTACT

[email protected]

352-294-5892

Ramzi Salloum, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adults aged 21 years or above (legal age for smoking in the U.S.) up to 75 years old;
  • self-reported smoking at least 5 cigarettes/day for the past year with INTENTION to quit at time of screening visit;
  • expired carbon monoxide level of more than 8 ppm at recruitment;
  • willingness to participate in the proposed study, as indicated by signed informed consent;
  • access to a functional telephone;
  • expected presence in the study's geographical area for the next 4 months;
  • not currently enrolled in any smoking cessation programs per self report; and
  • female subjects of childbearing potential will be required to practice acceptable methods of birth control (the acceptable methods of birth control include birth control pills, Birth Control Shot, Birth Control Implant, IUD, Diaphragm, and cervical cap).
  • if a participant takes kava dietary supplement, a 2-week washout period is needed for the participant to initiate this study or if a participant participated in a kava trial before, such as the kava JEK trial, the participant could be enrolled if the inclusion criteria above are met, including the 2-week washout period.

Exclusion criteria

  • history of active cancer (other than non-melanoma skin cancer) within the past 2 years;
  • diagnosed with liver dysfunction or with previous liver diseases;
  • levels of alanine transaminase, aspartate transaminase, alkaline phosphatase or total bilirubin over limit of normal (ULN) range at prescreen;
  • inability to refrain from acetaminophen, alcohol (no more than one drink daily via self-report), or other potentially hepatotoxic substances;
  • are pregnant or nursing (lactating) or of childbearing age planning to become pregnant or unwilling to use adequate contraception during the study;
  • participant answered "Yes" to any of the Modified Ask Suicide Screening Questions questions 1 through 3, or refuses to answer all of the questions. If subject answers 'Yes' to question 4 but the most recent suicide attempt took place >12 months from screening visit then subject is still eligible.

Treatment and study plan

Placebo

Drug

Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.

AB-free kava

Drug

Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.

Primary outcomes

  1. Subject Compliance with Intervention

    Time frame: 4 weeks

    Evaluate subject compliance with the kava intervention, as measured by participant reported number of missed doses

  2. Subject Compliance with Intervention

    Time frame: 4 weeks

    Evaluate subject compliance with the kava intervention, as measured by detection of dihydromethysticin in participant urine by urine testing

Secondary outcomes

  1. Tobacco cessation

    Time frame: 12 weeks

    Examine whether kava has the potential to help facilitate tobacco cessation, as measured by participant reported number of cigarettes smoked

  2. Tobacco cessation

    Time frame: 12 weeks

    Examine whether kava has the potential to help facilitate tobacco cessation, as measured by the Fagerström Test for Nicotine Dependence (FTND)

  3. Tobacco cessation

    Time frame: 12 weeks

    Examine whether kava has the potential to help facilitate tobacco cessation, as measured by the Modified Cigarette Evaluation Questionnaire (mCEQ)

  4. Tobacco cessation

    Time frame: 12 weeks

    Examine whether kava has the potential to help facilitate tobacco cessation, as measured by the Brief Questionnaire on Smoking Urges (QSU-Brief)

  5. Tobacco cessation

    Time frame: 12 weeks

    Examine whether kava has the potential to help facilitate tobacco cessation, as measured by urinary total nicotine equivalents

  6. Effect on stress

    Time frame: 12 weeks

    Examine whether kava has the potential to reduce stress, as measured by the Perceived Stress Scale (PSS). The Perceived Stress Scale consists of 10 items that are each scored on a scale of 0-4. The maximum possible score for this instrument is 40 and the minimum score is 0. A higher score indicates greater perceived stress.

  7. Effect on stress

    Time frame: 12 weeks

    Examine whether kava has the potential to reduce stress, as measured by plasma PRKACA

  8. Effect on stress

    Time frame: 12 weeks

    Examine whether kava has the potential to reduce stress, as measured by plasma cortisol

  9. Effect on stress

    Time frame: 12 weeks

    Examine whether kava has the potential to reduce stress, as measured by urinary TCE

  10. Effect on stress

    Time frame: 12 weeks

    Examine whether kava has the potential to reduce stress, as measured by total cortisol equivalents

  11. Effect on sleep

    Time frame: 12 weeks

    Examine whether kava has the potential to improve sleep, as measured by the Insomnia Severity Scale. The Insomnia Severity Scale instrument consists of 7 items that are each scored on a scale of 0-4. The maximum possible score for this instrument is 28 and the minimum score is 0. A higher score indicates more severe insomnia.

  12. Effect on sleep

    Time frame: 12 weeks

    Examine whether kava has the potential to improve sleep, as measured by the Pittsburgh Sleep Quality Index (PSQI)

  13. Effect on sleep

    Time frame: 12 weeks

    Examine whether kava has the potential to improve sleep, as measured by urinary 6-hydroxymelatonin

  14. Effect on sleep

    Time frame: 12 weeks

    Examine whether kava has the potential to improve sleep, as measured by urinary N-acetyl serotonin

  15. Effect on sleep

    Time frame: 12 weeks

    Examine whether kava has the potential to improve sleep, as measured by urinary NAS

Study contacts

Contact information is provided by the study sponsor or research team.

Chengguo Dr. Xing

CONTACT

[email protected]

352-294-8511

Ramzi G Dr. Salloum

CONTACT

[email protected]

352-294-4997

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)
  • National Institutes of Health (NIH)

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Apr 14, 2023
Registry last updated
Jan 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.